Benjamin Bitler
Concepts (359)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Ovarian Neoplasms | 34 | 2024 | 386 | 9.600 |
Why?
| Poly(ADP-ribose) Polymerase Inhibitors | 9 | 2023 | 68 | 3.710 |
Why?
| Cystadenocarcinoma, Serous | 5 | 2023 | 43 | 3.100 |
Why?
| Fallopian Tubes | 3 | 2024 | 29 | 1.800 |
Why?
| Nuclear Proteins | 10 | 2018 | 591 | 1.700 |
Why?
| Transcription Factors | 13 | 2023 | 1526 | 1.570 |
Why?
| Drug Resistance, Neoplasm | 8 | 2023 | 637 | 1.550 |
Why?
| Cell Line, Tumor | 29 | 2023 | 2699 | 1.550 |
Why?
| Phthalazines | 3 | 2019 | 38 | 1.430 |
Why?
| Piperazines | 3 | 2019 | 310 | 1.240 |
Why?
| Cellular Senescence | 7 | 2019 | 151 | 1.150 |
Why?
| Antineoplastic Agents | 6 | 2023 | 1875 | 1.020 |
Why?
| Neoplasms | 6 | 2023 | 2089 | 0.970 |
Why?
| Tumor Microenvironment | 5 | 2023 | 428 | 0.940 |
Why?
| BRCA2 Protein | 4 | 2022 | 41 | 0.920 |
Why?
| Gene Expression Regulation, Neoplastic | 16 | 2021 | 1144 | 0.890 |
Why?
| Mucin-1 | 4 | 2012 | 18 | 0.840 |
Why?
| Polycomb Repressive Complex 1 | 1 | 2023 | 38 | 0.830 |
Why?
| Ovary | 2 | 2022 | 190 | 0.830 |
Why?
| DNA-Binding Proteins | 9 | 2020 | 1311 | 0.800 |
Why?
| Histone-Lysine N-Methyltransferase | 2 | 2021 | 96 | 0.790 |
Why?
| Protein-Arginine N-Methyltransferases | 2 | 2019 | 16 | 0.780 |
Why?
| Mutation | 10 | 2022 | 3338 | 0.780 |
Why?
| Neoplasms, Cystic, Mucinous, and Serous | 2 | 2021 | 25 | 0.760 |
Why?
| Neoplasms, Glandular and Epithelial | 4 | 2018 | 34 | 0.750 |
Why?
| Breast Neoplasms | 5 | 2024 | 1846 | 0.750 |
Why?
| Programmed Cell Death 1 Receptor | 1 | 2022 | 193 | 0.730 |
Why?
| Ascites | 1 | 2021 | 32 | 0.720 |
Why?
| Up-Regulation | 5 | 2020 | 802 | 0.710 |
Why?
| Female | 47 | 2024 | 59349 | 0.710 |
Why?
| Cytoreduction Surgical Procedures | 1 | 2020 | 39 | 0.700 |
Why?
| Epoxy Compounds | 1 | 2020 | 31 | 0.680 |
Why?
| Indoles | 3 | 2019 | 300 | 0.680 |
Why?
| Poly(ADP-ribose) Polymerases | 2 | 2019 | 87 | 0.670 |
Why?
| Carnitine O-Palmitoyltransferase | 1 | 2020 | 43 | 0.670 |
Why?
| Rad51 Recombinase | 1 | 2019 | 14 | 0.670 |
Why?
| Chemotherapy, Adjuvant | 1 | 2020 | 332 | 0.650 |
Why?
| Histocompatibility Antigens | 1 | 2019 | 98 | 0.640 |
Why?
| Wnt Signaling Pathway | 4 | 2021 | 146 | 0.620 |
Why?
| Neoadjuvant Therapy | 1 | 2020 | 305 | 0.610 |
Why?
| Membrane Proteins | 4 | 2019 | 1016 | 0.590 |
Why?
| Mice | 23 | 2023 | 14847 | 0.590 |
Why?
| Pyridones | 2 | 2018 | 122 | 0.590 |
Why?
| Polycomb Repressive Complex 2 | 3 | 2015 | 59 | 0.570 |
Why?
| Xenograft Model Antitumor Assays | 6 | 2020 | 695 | 0.570 |
Why?
| Humans | 58 | 2024 | 114080 | 0.570 |
Why?
| Fatty Acids | 1 | 2020 | 380 | 0.560 |
Why?
| ErbB Receptors | 4 | 2023 | 554 | 0.530 |
Why?
| Wnt Proteins | 2 | 2021 | 134 | 0.520 |
Why?
| Enhancer of Zeste Homolog 2 Protein | 6 | 2020 | 37 | 0.520 |
Why?
| Animals | 31 | 2023 | 31570 | 0.510 |
Why?
| Histone Deacetylases | 1 | 2017 | 194 | 0.500 |
Why?
| Endometrial Neoplasms | 3 | 2022 | 141 | 0.490 |
Why?
| Methyltransferases | 1 | 2015 | 61 | 0.460 |
Why?
| Molecular Targeted Therapy | 2 | 2021 | 347 | 0.440 |
Why?
| Peptides | 3 | 2023 | 847 | 0.440 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 1356 | 0.430 |
Why?
| Anoikis | 3 | 2023 | 31 | 0.430 |
Why?
| Proto-Oncogene Proteins c-akt | 1 | 2015 | 397 | 0.410 |
Why?
| Biological Assay | 1 | 2013 | 112 | 0.410 |
Why?
| Cell Proliferation | 10 | 2021 | 2173 | 0.410 |
Why?
| Small Molecule Libraries | 1 | 2013 | 79 | 0.410 |
Why?
| Azepines | 3 | 2017 | 69 | 0.410 |
Why?
| Gene Expression Profiling | 6 | 2023 | 1519 | 0.390 |
Why?
| Histones | 3 | 2023 | 529 | 0.390 |
Why?
| Triazoles | 3 | 2017 | 125 | 0.380 |
Why?
| Inflammation | 2 | 2023 | 2465 | 0.370 |
Why?
| Claudin-4 | 2 | 2022 | 9 | 0.360 |
Why?
| Signal Transduction | 7 | 2024 | 4501 | 0.350 |
Why?
| Cells | 1 | 2010 | 22 | 0.340 |
Why?
| Carcinogenesis | 2 | 2022 | 175 | 0.330 |
Why?
| Fibroblasts | 1 | 2013 | 836 | 0.310 |
Why?
| BRCA1 Protein | 3 | 2021 | 56 | 0.310 |
Why?
| B7-H1 Antigen | 2 | 2022 | 137 | 0.310 |
Why?
| Carcinoma | 1 | 2010 | 198 | 0.300 |
Why?
| Mice, Transgenic | 5 | 2019 | 1947 | 0.300 |
Why?
| RNA, Small Interfering | 5 | 2020 | 534 | 0.300 |
Why?
| Piperidines | 2 | 2019 | 159 | 0.290 |
Why?
| Proto-Oncogene Proteins | 1 | 2011 | 607 | 0.290 |
Why?
| Protein Kinase Inhibitors | 1 | 2013 | 784 | 0.290 |
Why?
| Tumor Suppressor Protein p53 | 3 | 2022 | 445 | 0.290 |
Why?
| DNA Repair | 3 | 2022 | 184 | 0.280 |
Why?
| Drug Delivery Systems | 1 | 2010 | 295 | 0.280 |
Why?
| Neoplasm Grading | 4 | 2022 | 241 | 0.280 |
Why?
| Cell Nucleus | 1 | 2010 | 552 | 0.280 |
Why?
| beta Catenin | 3 | 2022 | 218 | 0.270 |
Why?
| Peptide Fragments | 1 | 2010 | 665 | 0.260 |
Why?
| Histone Deacetylase Inhibitors | 2 | 2018 | 197 | 0.260 |
Why?
| Oncogenes | 2 | 2019 | 104 | 0.250 |
Why?
| Disease Progression | 7 | 2020 | 2371 | 0.250 |
Why?
| Biomarkers, Tumor | 4 | 2022 | 1032 | 0.250 |
Why?
| Lysine | 2 | 2023 | 241 | 0.230 |
Why?
| Ligands | 2 | 2024 | 556 | 0.230 |
Why?
| Repressor Proteins | 2 | 2018 | 367 | 0.230 |
Why?
| Wnt4 Protein | 2 | 2024 | 17 | 0.220 |
Why?
| Lymphocytes, Tumor-Infiltrating | 2 | 2021 | 111 | 0.220 |
Why?
| Prognosis | 2 | 2022 | 3315 | 0.220 |
Why?
| Apoptosis | 5 | 2019 | 2349 | 0.220 |
Why?
| DNA Damage | 3 | 2022 | 351 | 0.220 |
Why?
| Aldehyde Dehydrogenase | 2 | 2016 | 102 | 0.220 |
Why?
| Polycomb-Group Proteins | 1 | 2023 | 29 | 0.210 |
Why?
| Cell Movement | 3 | 2018 | 863 | 0.210 |
Why?
| Activating Transcription Factor 6 | 1 | 2023 | 16 | 0.210 |
Why?
| Genital Neoplasms, Female | 1 | 2024 | 70 | 0.210 |
Why?
| Retinoblastoma-Binding Protein 2 | 1 | 2022 | 3 | 0.200 |
Why?
| Indazoles | 2 | 2021 | 57 | 0.200 |
Why?
| Transcription Factor AP-1 | 1 | 2023 | 81 | 0.200 |
Why?
| Cell Cycle Checkpoints | 4 | 2019 | 84 | 0.200 |
Why?
| X-ray Repair Cross Complementing Protein 1 | 1 | 2022 | 14 | 0.200 |
Why?
| Down-Regulation | 4 | 2022 | 594 | 0.200 |
Why?
| Tripartite Motif-Containing Protein 28 | 1 | 2021 | 6 | 0.200 |
Why?
| Tumor Cells, Cultured | 3 | 2019 | 845 | 0.190 |
Why?
| Carcinoma, Endometrioid | 1 | 2022 | 46 | 0.190 |
Why?
| Granulosa Cells | 1 | 2021 | 29 | 0.190 |
Why?
| Promoter Regions, Genetic | 3 | 2017 | 1131 | 0.190 |
Why?
| Antigen Presentation | 1 | 2022 | 188 | 0.190 |
Why?
| Proteins | 2 | 2017 | 906 | 0.190 |
Why?
| Transfection | 3 | 2021 | 863 | 0.180 |
Why?
| RNA Interference | 3 | 2019 | 431 | 0.180 |
Why?
| Ovarian Follicle | 1 | 2021 | 61 | 0.180 |
Why?
| Epigenomics | 1 | 2021 | 98 | 0.180 |
Why?
| Transcriptome | 2 | 2023 | 721 | 0.180 |
Why?
| Gene Knockdown Techniques | 2 | 2020 | 300 | 0.180 |
Why?
| Chromatin | 2 | 2016 | 424 | 0.180 |
Why?
| Immunotherapy | 2 | 2021 | 473 | 0.180 |
Why?
| Cell Culture Techniques | 2 | 2020 | 341 | 0.180 |
Why?
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2021 | 86 | 0.180 |
Why?
| Neoplasm Recurrence, Local | 2 | 2023 | 850 | 0.180 |
Why?
| Immunity | 2 | 2022 | 121 | 0.170 |
Why?
| Germ-Line Mutation | 1 | 2021 | 131 | 0.170 |
Why?
| Wnt3A Protein | 1 | 2019 | 7 | 0.170 |
Why?
| Diagnostic Imaging | 1 | 2022 | 278 | 0.170 |
Why?
| Neoplasm Transplantation | 2 | 2011 | 227 | 0.170 |
Why?
| Acyltransferases | 1 | 2019 | 46 | 0.170 |
Why?
| Receptors, Adiponectin | 1 | 2019 | 15 | 0.160 |
Why?
| Gene Frequency | 1 | 2021 | 476 | 0.160 |
Why?
| Sequence Analysis, DNA | 2 | 2021 | 722 | 0.160 |
Why?
| Survival Rate | 2 | 2020 | 1638 | 0.160 |
Why?
| Image Processing, Computer-Assisted | 1 | 2023 | 684 | 0.160 |
Why?
| E2F Transcription Factors | 1 | 2019 | 55 | 0.160 |
Why?
| Amino Acid Sequence | 4 | 2015 | 1981 | 0.160 |
Why?
| Protein Processing, Post-Translational | 2 | 2021 | 399 | 0.160 |
Why?
| NF-kappa B | 1 | 2023 | 636 | 0.160 |
Why?
| Isocitrate Dehydrogenase | 1 | 2019 | 38 | 0.160 |
Why?
| Heterografts | 1 | 2019 | 117 | 0.160 |
Why?
| CA-125 Antigen | 1 | 2018 | 12 | 0.160 |
Why?
| Chloride Channels | 1 | 2018 | 35 | 0.150 |
Why?
| RNA Splicing Factors | 1 | 2018 | 49 | 0.150 |
Why?
| Drug Repositioning | 1 | 2018 | 13 | 0.150 |
Why?
| Genetic Testing | 1 | 2021 | 381 | 0.150 |
Why?
| Chromosomal Proteins, Non-Histone | 1 | 2018 | 100 | 0.150 |
Why?
| Paclitaxel | 1 | 2019 | 190 | 0.150 |
Why?
| Cell Cycle Proteins | 4 | 2017 | 549 | 0.150 |
Why?
| Mice, SCID | 3 | 2018 | 312 | 0.150 |
Why?
| Histone Deacetylase 6 | 1 | 2017 | 19 | 0.140 |
Why?
| Combined Modality Therapy | 1 | 2020 | 1117 | 0.140 |
Why?
| Uterine Cervical Neoplasms | 1 | 2020 | 213 | 0.140 |
Why?
| Antineoplastic Agents, Phytogenic | 1 | 2019 | 182 | 0.140 |
Why?
| Sequence Analysis, RNA | 1 | 2019 | 388 | 0.140 |
Why?
| Class I Phosphatidylinositol 3-Kinases | 1 | 2017 | 76 | 0.140 |
Why?
| Heterochromatin | 2 | 2016 | 32 | 0.140 |
Why?
| Claudins | 1 | 2017 | 24 | 0.140 |
Why?
| Alternative Splicing | 1 | 2018 | 186 | 0.140 |
Why?
| HMGB2 Protein | 1 | 2016 | 4 | 0.140 |
Why?
| Secretory Pathway | 1 | 2016 | 5 | 0.140 |
Why?
| Mevalonic Acid | 1 | 2016 | 7 | 0.140 |
Why?
| Oxidation-Reduction | 1 | 2020 | 917 | 0.140 |
Why?
| Acetylation | 1 | 2017 | 209 | 0.140 |
Why?
| Adenocarcinoma, Clear Cell | 1 | 2016 | 14 | 0.130 |
Why?
| Tight Junctions | 1 | 2017 | 68 | 0.130 |
Why?
| Intracellular Signaling Peptides and Proteins | 2 | 2019 | 388 | 0.130 |
Why?
| Biomarkers | 2 | 2024 | 3397 | 0.130 |
Why?
| Mass Spectrometry | 1 | 2019 | 622 | 0.130 |
Why?
| Transcription, Genetic | 3 | 2017 | 1310 | 0.130 |
Why?
| Tumor Burden | 1 | 2017 | 258 | 0.130 |
Why?
| Mammary Glands, Animal | 1 | 2017 | 117 | 0.130 |
Why?
| Genetics, Population | 2 | 2008 | 187 | 0.130 |
Why?
| RNA, Long Noncoding | 1 | 2018 | 154 | 0.130 |
Why?
| Immunity, Innate | 1 | 2021 | 720 | 0.130 |
Why?
| Mice, Nude | 2 | 2015 | 628 | 0.130 |
Why?
| Gene Expression Regulation, Enzymologic | 1 | 2017 | 270 | 0.130 |
Why?
| Neoplasm Invasiveness | 1 | 2017 | 438 | 0.130 |
Why?
| Endopeptidases | 1 | 2015 | 70 | 0.120 |
Why?
| Phosphatidylinositol 3-Kinases | 1 | 2017 | 328 | 0.120 |
Why?
| Oxidative Stress | 1 | 2021 | 1068 | 0.120 |
Why?
| Genetic Loci | 1 | 2016 | 262 | 0.120 |
Why?
| T-Lymphocytes | 1 | 2022 | 1735 | 0.120 |
Why?
| Epithelial Cells | 2 | 2017 | 946 | 0.120 |
Why?
| Tomography, X-Ray Computed | 1 | 2023 | 2273 | 0.110 |
Why?
| Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 959 | 0.110 |
Why?
| Oncogene Protein p21(ras) | 1 | 2013 | 16 | 0.110 |
Why?
| Pyrimidine Nucleotides | 1 | 2013 | 2 | 0.110 |
Why?
| beta-Galactosidase | 1 | 2013 | 62 | 0.110 |
Why?
| Purine Nucleotides | 1 | 2013 | 12 | 0.110 |
Why?
| CCAAT-Binding Factor | 1 | 2013 | 4 | 0.110 |
Why?
| Dose-Response Relationship, Drug | 1 | 2017 | 1837 | 0.110 |
Why?
| Proteome | 1 | 2016 | 337 | 0.100 |
Why?
| Primary Cell Culture | 1 | 2013 | 148 | 0.100 |
Why?
| Genes, Reporter | 1 | 2013 | 256 | 0.100 |
Why?
| Proto-Oncogene Proteins c-met | 1 | 2012 | 67 | 0.100 |
Why?
| Gene Expression Regulation, Developmental | 1 | 2017 | 801 | 0.100 |
Why?
| Follow-Up Studies | 1 | 2020 | 4392 | 0.100 |
Why?
| RNA Helicases | 1 | 2011 | 20 | 0.100 |
Why?
| Wnt-5a Protein | 1 | 2011 | 18 | 0.100 |
Why?
| Genes, ras | 1 | 2011 | 91 | 0.090 |
Why?
| Golgi Apparatus | 1 | 2011 | 89 | 0.090 |
Why?
| Molecular Sequence Data | 3 | 2015 | 2783 | 0.090 |
Why?
| Gene Flow | 2 | 2008 | 76 | 0.090 |
Why?
| Cell Line | 4 | 2021 | 2629 | 0.090 |
Why?
| Models, Biological | 3 | 2019 | 1611 | 0.090 |
Why?
| AMP-Activated Protein Kinases | 2 | 2024 | 170 | 0.090 |
Why?
| Gene Expression Regulation | 3 | 2016 | 2322 | 0.090 |
Why?
| Endosomes | 1 | 2011 | 122 | 0.090 |
Why?
| Cyclin D1 | 1 | 2010 | 61 | 0.090 |
Why?
| Aged, 80 and over | 1 | 2021 | 6307 | 0.080 |
Why?
| Lung Neoplasms | 1 | 2022 | 2159 | 0.080 |
Why?
| Active Transport, Cell Nucleus | 1 | 2010 | 109 | 0.080 |
Why?
| Protein Binding | 2 | 2016 | 1888 | 0.080 |
Why?
| Caenorhabditis elegans Proteins | 1 | 2011 | 180 | 0.080 |
Why?
| Arachnida | 1 | 2008 | 4 | 0.080 |
Why?
| Cloning, Molecular | 1 | 2010 | 522 | 0.080 |
Why?
| Prostatic Neoplasms | 1 | 2015 | 913 | 0.080 |
Why?
| Mammary Neoplasms, Experimental | 1 | 2009 | 64 | 0.080 |
Why?
| Neoplasm Metastasis | 3 | 2020 | 521 | 0.070 |
Why?
| Cytoplasm | 1 | 2009 | 255 | 0.070 |
Why?
| Immunohistochemistry | 2 | 2022 | 1624 | 0.070 |
Why?
| Neoplasm Staging | 1 | 2011 | 1162 | 0.070 |
Why?
| Trans-Activators | 1 | 2010 | 366 | 0.070 |
Why?
| Mammary Neoplasms, Animal | 1 | 2007 | 28 | 0.070 |
Why?
| Transforming Growth Factor alpha | 1 | 2007 | 53 | 0.070 |
Why?
| Cactaceae | 1 | 2006 | 5 | 0.070 |
Why?
| Triatoma | 1 | 2006 | 5 | 0.070 |
Why?
| Middle Aged | 3 | 2021 | 26621 | 0.070 |
Why?
| Phylogeny | 2 | 2008 | 787 | 0.070 |
Why?
| Mice, Inbred NOD | 2 | 2018 | 552 | 0.070 |
Why?
| Protein Structure, Tertiary | 1 | 2009 | 796 | 0.070 |
Why?
| Aged | 2 | 2021 | 18973 | 0.060 |
Why?
| Epigenesis, Genetic | 2 | 2020 | 517 | 0.060 |
Why?
| Drosophila | 1 | 2006 | 133 | 0.060 |
Why?
| Genetic Variation | 2 | 2008 | 868 | 0.060 |
Why?
| Evolution, Molecular | 1 | 2008 | 429 | 0.060 |
Why?
| Protein Transport | 2 | 2019 | 391 | 0.060 |
Why?
| Retinal Dehydrogenase | 2 | 2016 | 33 | 0.060 |
Why?
| Carbonyl Reductase (NADPH) | 1 | 2024 | 4 | 0.060 |
Why?
| Signal-To-Noise Ratio | 1 | 2023 | 56 | 0.050 |
Why?
| Cytokine TWEAK | 1 | 2023 | 1 | 0.050 |
Why?
| Transcription Factor RelB | 1 | 2023 | 4 | 0.050 |
Why?
| TWEAK Receptor | 1 | 2023 | 5 | 0.050 |
Why?
| Tumor Necrosis Factors | 1 | 2023 | 9 | 0.050 |
Why?
| Muscular Atrophy | 1 | 2023 | 78 | 0.050 |
Why?
| Cachexia | 1 | 2023 | 52 | 0.050 |
Why?
| Artifacts | 1 | 2023 | 114 | 0.050 |
Why?
| Recombinational DNA Repair | 1 | 2022 | 9 | 0.050 |
Why?
| Homologous Recombination | 1 | 2022 | 20 | 0.050 |
Why?
| Carboplatin | 1 | 2023 | 135 | 0.050 |
Why?
| Receptors, Tumor Necrosis Factor | 1 | 2023 | 140 | 0.050 |
Why?
| Cell Cycle | 2 | 2017 | 541 | 0.050 |
Why?
| Genomics | 1 | 2006 | 631 | 0.050 |
Why?
| Oligonucleotide Array Sequence Analysis | 2 | 2016 | 742 | 0.050 |
Why?
| Eukaryotic Initiation Factor-2 | 1 | 2021 | 24 | 0.050 |
Why?
| Mice, Inbred C57BL | 3 | 2018 | 4682 | 0.050 |
Why?
| Heterocyclic Compounds, 3-Ring | 1 | 2021 | 28 | 0.050 |
Why?
| Open Reading Frames | 1 | 2021 | 117 | 0.050 |
Why?
| Cluster Analysis | 1 | 2022 | 452 | 0.040 |
Why?
| Imidazoles | 1 | 2021 | 203 | 0.040 |
Why?
| Tumor Escape | 1 | 2020 | 35 | 0.040 |
Why?
| Cell Division | 1 | 2021 | 754 | 0.040 |
Why?
| Culture Media, Conditioned | 1 | 2019 | 103 | 0.040 |
Why?
| Computer Simulation | 1 | 2023 | 873 | 0.040 |
Why?
| Paracrine Communication | 1 | 2019 | 55 | 0.040 |
Why?
| Protein Biosynthesis | 1 | 2021 | 386 | 0.040 |
Why?
| Chromatin Assembly and Disassembly | 1 | 2020 | 88 | 0.040 |
Why?
| Disease Susceptibility | 1 | 2021 | 316 | 0.040 |
Why?
| Coculture Techniques | 1 | 2019 | 198 | 0.040 |
Why?
| Immunophenotyping | 1 | 2020 | 274 | 0.040 |
Why?
| Interferons | 1 | 2020 | 151 | 0.040 |
Why?
| Blotting, Western | 2 | 2011 | 1143 | 0.040 |
Why?
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2019 | 97 | 0.040 |
Why?
| Flow Cytometry | 1 | 2022 | 1075 | 0.040 |
Why?
| Stem Cells | 1 | 2023 | 541 | 0.040 |
Why?
| Aniline Compounds | 1 | 2018 | 70 | 0.040 |
Why?
| Gene Amplification | 1 | 2018 | 95 | 0.040 |
Why?
| Survival Analysis | 1 | 2021 | 1206 | 0.040 |
Why?
| Recurrence | 1 | 2021 | 925 | 0.040 |
Why?
| Mitosis | 1 | 2019 | 164 | 0.040 |
Why?
| Cell Survival | 1 | 2021 | 1014 | 0.040 |
Why?
| Receptors, G-Protein-Coupled | 1 | 2019 | 186 | 0.040 |
Why?
| Desert Climate | 2 | 2008 | 12 | 0.040 |
Why?
| Pyridines | 1 | 2021 | 419 | 0.040 |
Why?
| Arizona | 2 | 2008 | 68 | 0.040 |
Why?
| DNA Helicases | 1 | 2018 | 133 | 0.040 |
Why?
| Disease Management | 1 | 2021 | 556 | 0.040 |
Why?
| Mexico | 2 | 2008 | 162 | 0.040 |
Why?
| Phosphorylation | 1 | 2021 | 1559 | 0.030 |
Why?
| Epithelial-Mesenchymal Transition | 1 | 2018 | 167 | 0.030 |
Why?
| Drug Synergism | 1 | 2017 | 315 | 0.030 |
Why?
| Algorithms | 1 | 2023 | 1469 | 0.030 |
Why?
| DNA, Mitochondrial | 2 | 2008 | 182 | 0.030 |
Why?
| Tumor Necrosis Factor-alpha | 1 | 2021 | 1128 | 0.030 |
Why?
| Gene Knockout Techniques | 1 | 2016 | 98 | 0.030 |
Why?
| Lactation | 1 | 2017 | 149 | 0.030 |
Why?
| T-Lymphocytes, Cytotoxic | 1 | 2016 | 154 | 0.030 |
Why?
| Sumoylation | 1 | 2015 | 15 | 0.030 |
Why?
| Metabolic Networks and Pathways | 1 | 2016 | 167 | 0.030 |
Why?
| Cisplatin | 1 | 2016 | 262 | 0.030 |
Why?
| Sulfonamides | 1 | 2018 | 444 | 0.030 |
Why?
| Proteolysis | 1 | 2015 | 142 | 0.030 |
Why?
| Gene Silencing | 1 | 2015 | 171 | 0.030 |
Why?
| Models, Genetic | 2 | 2008 | 559 | 0.030 |
Why?
| Chromatography, Liquid | 1 | 2016 | 345 | 0.030 |
Why?
| Muscle, Skeletal | 1 | 2023 | 1468 | 0.030 |
Why?
| Protein-Tyrosine Kinases | 1 | 2017 | 393 | 0.030 |
Why?
| Mice, Inbred BALB C | 1 | 2017 | 1144 | 0.030 |
Why?
| Tandem Mass Spectrometry | 1 | 2016 | 410 | 0.030 |
Why?
| Melanoma | 1 | 2020 | 620 | 0.030 |
Why?
| E2F7 Transcription Factor | 1 | 2013 | 1 | 0.030 |
Why?
| HEK293 Cells | 1 | 2015 | 589 | 0.030 |
Why?
| Ribonucleoside Diphosphate Reductase | 1 | 2013 | 4 | 0.030 |
Why?
| Nucleosides | 1 | 2013 | 25 | 0.030 |
Why?
| Cell Growth Processes | 1 | 2013 | 51 | 0.030 |
Why?
| Mice, Knockout | 1 | 2018 | 2563 | 0.030 |
Why?
| Time Factors | 2 | 2016 | 6077 | 0.020 |
Why?
| Epidermal Growth Factor | 1 | 2012 | 160 | 0.020 |
Why?
| ras Proteins | 1 | 2013 | 138 | 0.020 |
Why?
| Fanconi Anemia Complementation Group Proteins | 1 | 2011 | 6 | 0.020 |
Why?
| Genes, BRCA1 | 1 | 2011 | 31 | 0.020 |
Why?
| Sorting Nexins | 1 | 2011 | 10 | 0.020 |
Why?
| Two-Hybrid System Techniques | 1 | 2011 | 52 | 0.020 |
Why?
| Chromatin Immunoprecipitation | 1 | 2011 | 128 | 0.020 |
Why?
| Proto-Oncogene Proteins B-raf | 1 | 2013 | 191 | 0.020 |
Why?
| Immunoprecipitation | 1 | 2011 | 151 | 0.020 |
Why?
| Real-Time Polymerase Chain Reaction | 1 | 2011 | 314 | 0.020 |
Why?
| Endocytosis | 1 | 2011 | 146 | 0.020 |
Why?
| Protein Folding | 1 | 2011 | 239 | 0.020 |
Why?
| HeLa Cells | 1 | 2011 | 563 | 0.020 |
Why?
| Cell Transformation, Neoplastic | 1 | 2011 | 307 | 0.020 |
Why?
| Phenotype | 1 | 2016 | 2784 | 0.020 |
Why?
| Recombinant Fusion Proteins | 1 | 2011 | 613 | 0.020 |
Why?
| Caenorhabditis elegans | 1 | 2011 | 268 | 0.020 |
Why?
| Geography | 1 | 2008 | 176 | 0.020 |
Why?
| Population Dynamics | 1 | 2008 | 123 | 0.020 |
Why?
| Cells, Cultured | 1 | 2015 | 3862 | 0.020 |
Why?
| Haplotypes | 1 | 2008 | 448 | 0.020 |
Why?
| Genes, Insect | 1 | 2006 | 20 | 0.020 |
Why?
| Cytochromes b | 1 | 2006 | 10 | 0.020 |
Why?
| Insect Vectors | 1 | 2006 | 27 | 0.020 |
Why?
| Electron Transport Complex IV | 1 | 2006 | 53 | 0.020 |
Why?
| Lymphoma | 1 | 2007 | 176 | 0.020 |
Why?
| Chagas Disease | 1 | 2006 | 32 | 0.020 |
Why?
| Host-Parasite Interactions | 1 | 2006 | 94 | 0.020 |
Why?
| Pregnancy | 1 | 2017 | 5503 | 0.020 |
Why?
| Bayes Theorem | 1 | 2006 | 327 | 0.010 |
Why?
| Macrophages | 1 | 2011 | 1259 | 0.010 |
Why?
| RNA, Messenger | 1 | 2011 | 2550 | 0.010 |
Why?
| Firefly Luciferin | 1 | 1957 | 1 | 0.010 |
Why?
| Disease Models, Animal | 1 | 2007 | 3499 | 0.010 |
Why?
| Diptera | 1 | 1957 | 27 | 0.010 |
Why?
| Luciferases | 1 | 1957 | 142 | 0.010 |
Why?
| Male | 1 | 2015 | 55420 | 0.010 |
Why?
|
|
Bitler's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|